STAT

JANUARY 31, 2024

Overall, Novo saw 154% growth in obesity drug revenue in 2023, driven by sales of its older obesity drug Saxenda and the launch of Wegovy in additional countries. In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S.

Diabetes 212

Diabetes 212

Fuld & Company Blog

MARCH 27, 2023

Wegovy goes mainstream By December 2020, Novo had further developed its move into the weight loss market when it received approval for its recombinant GLP-1, Saxenda , approved for chronic weight management, but this only provided marginal weight loss in trial. The only difference between Wegovy and Ozempic is the approved maintenance dose.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98